Chiroptical spectroscopy of human blood plasma: Revealing the signature of degenerative diseases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22340%2F16%3A43903344" target="_blank" >RIV/60461373:22340/16:43903344 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Chiroptical spectroscopy of human blood plasma: Revealing the signature of degenerative diseases

Popis výsledku v původním jazyce

The greatest advantage of chiroptical spectroscopy is its inherent sensitivity to the structure and conformation of chiral biomolecules, such as peptides, proteins, saccharides or nucleic acids. However except our recent studies, it has never been used for a systematic analysis of biofluids. As blood-based testing represents a basis for a future sensitive screening of populations at risk of various degenerative diseases, we focus on the analysis of blood plasma using Raman optical activity (ROA) and electronic circular dichroism. To gain more detailed structure information, chiroptical methods are supplemented by conventional Raman and infrared spectroscopies. Unfortunately, blood plasma is rich in molecules that may generate a background of large amplitude overlapping the desired ROA and Raman signals. To enable the measurements and to improve the reliability of the data acquired, we developed a methodology for the minimization of background fluorescence. Using the combination of the above mentioned methods, we monitored the specific molecular signature of blood plasma components and the differences thereof in healthy subjects and patients with pancreatic cancer and diabetes mellitus. Focusing on the spectral regions that reflect the structure of essential biomolecules, the obtained data sets were statistically evaluated yielding high values of specificity and sensitivity. The achieved results indicate a promising potential of the combination of chiroptical and vibrational spectroscopies as a powerful tool in the identification of disease-related structural changes of chiral biomolecules within blood plasma.

Název v anglickém jazyce

Chiroptical spectroscopy of human blood plasma: Revealing the signature of degenerative diseases

Popis výsledku anglicky

The greatest advantage of chiroptical spectroscopy is its inherent sensitivity to the structure and conformation of chiral biomolecules, such as peptides, proteins, saccharides or nucleic acids. However except our recent studies, it has never been used for a systematic analysis of biofluids. As blood-based testing represents a basis for a future sensitive screening of populations at risk of various degenerative diseases, we focus on the analysis of blood plasma using Raman optical activity (ROA) and electronic circular dichroism. To gain more detailed structure information, chiroptical methods are supplemented by conventional Raman and infrared spectroscopies. Unfortunately, blood plasma is rich in molecules that may generate a background of large amplitude overlapping the desired ROA and Raman signals. To enable the measurements and to improve the reliability of the data acquired, we developed a methodology for the minimization of background fluorescence. Using the combination of the above mentioned methods, we monitored the specific molecular signature of blood plasma components and the differences thereof in healthy subjects and patients with pancreatic cancer and diabetes mellitus. Focusing on the spectral regions that reflect the structure of essential biomolecules, the obtained data sets were statistically evaluated yielding high values of specificity and sensitivity. The achieved results indicate a promising potential of the combination of chiroptical and vibrational spectroscopies as a powerful tool in the identification of disease-related structural changes of chiral biomolecules within blood plasma.

Druh

O - Ostatní výsledky

CEP obor

CB - Analytická chemie, separace

OECD FORD obor

—

Projekt

<a href="/cs/project/NV16-31028A" target="_blank" >NV16-31028A: Účinnost nových spektroskopických biomarkerů pro detekci časného stádia karcinomu pankreatu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů